Arax Advisory Partners’s Immunome IMNM Stock Holding History
Bought
Maintained
Sold
Other funds holding IMNM
Arax Advisory Partners's IMNM Position: Q3 2026 in Review
Arax Advisory Partners increased its Immunome (IMNM) stake by 0.88% in Q3 2026, buying an estimated $25 and bringing the position to 115 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #4854.
Arax Advisory Partners first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.
- Arax Advisory Partners held 115 shares of Immunome worth $2.47K as of Q3 2026.
- Arax Advisory Partners bought 1 Immunome share in Q3 2026, an estimated $25.
- Immunome made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4854 holding.
- Arax Advisory Partners first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
- 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.